WO1994028922B1 - Treatment of neuromuscular disorders and conditions with different botulinum serotype - Google Patents
Treatment of neuromuscular disorders and conditions with different botulinum serotypeInfo
- Publication number
- WO1994028922B1 WO1994028922B1 PCT/US1994/006397 US9406397W WO9428922B1 WO 1994028922 B1 WO1994028922 B1 WO 1994028922B1 US 9406397 W US9406397 W US 9406397W WO 9428922 B1 WO9428922 B1 WO 9428922B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- patient
- botulinum toxin
- toxin type
- therapeutically effective
- effective amount
- Prior art date
Links
- 208000006883 Neuromuscular Disease Diseases 0.000 title 1
- 108010069023 botulinum toxin type E Proteins 0.000 claims 4
- 229940094657 Botulinum Toxin Type A Drugs 0.000 claims 3
- 108010057266 Type A Botulinum Toxins Proteins 0.000 claims 3
- 208000005392 Spasm Diseases 0.000 claims 2
- 108010061543 Neutralizing Antibodies Proteins 0.000 claims 1
- 108010043024 Botulinum Toxins Proteins 0.000 abstract 3
- 229940053031 botulinum toxin Drugs 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
Abstract
A method of treating a patient suffering from a disease, disorder or condition includes the administration to the patient of a therapeutically effective amount of botulinum toxin of a selected serotype until the patient experiences loss of clinical response to the administered botulinum toxin and thereafter administering to the patient a therapeutically effective amount of another botulinum toxin of a different serotype.
Claims
1. A method of administering to a patient suffering from muscular spasms, said method comprising injecting the patient with a therapeutically effective amount of botulinum toxin Type A until the patient experiences loss of clinical response to the injected botulinum toxin Type A and thereafter injecting the patient with botulinum toxin Type E, said botulinum toxin Type E being injected in therapeutically effective amounts.
2. A method of administering to a patient suffering from muscular spasms, said method comprising injecting the patient with a therapeutically effective amount of botulinum toxin Type A until the patient develops neutralizing antibodies and thereafter administering to the patient botulinum toxin Type E, said botulinum toxin Type E being administered in a therapeutically effective amount.
STATEMENT UNDER ARTICLE 19
In response to an International Search Report, mailed 21 October 1994, the Applicant has limited the scope of the claims to the apparatus of the invention. No new matter is added by this amendment as the new claims correspond to originally filed claims as indicated in the letter accompanying the replacement pages. The present amendment replacing claims does not affect the original description or the original drawings.
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002164866A CA2164866C (en) | 1993-06-10 | 1994-06-07 | Treatment of neuromuscular disorders and conditions with different botulinum serotype |
| DE69429619T DE69429619T2 (en) | 1993-06-10 | 1994-06-07 | TREATMENT OF NEUROMUSCULAR DISORDERS AND CONDITIONS WITH BOTULISM SEROTYPE E |
| EP94920705A EP0702561B1 (en) | 1993-06-10 | 1994-06-07 | Treatment of neuromuscular disorders and conditions with botulinum serotyp e |
| JP7502041A JPH08511536A (en) | 1993-06-10 | 1994-06-07 | Methods for treating neuromuscular diseases and conditions with multiple serotypes of botulinum toxin |
| AU70878/94A AU689115B2 (en) | 1993-06-10 | 1994-06-07 | Treatment of neuromuscular disorders and conditions with different botulinum serotype |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7504893A | 1993-06-10 | 1993-06-10 | |
| US08/075,048 | 1993-06-10 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1994028922A1 WO1994028922A1 (en) | 1994-12-22 |
| WO1994028922B1 true WO1994028922B1 (en) | 1995-01-26 |
Family
ID=22123211
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1994/006397 WO1994028922A1 (en) | 1993-06-10 | 1994-06-07 | Treatment of neuromuscular disorders and conditions with different botulinum serotype |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US6872397B2 (en) |
| EP (7) | EP1508336B1 (en) |
| JP (4) | JPH08511536A (en) |
| AU (1) | AU689115B2 (en) |
| CA (3) | CA2332406C (en) |
| DE (6) | DE69429619T2 (en) |
| ES (5) | ES2329232T3 (en) |
| HK (1) | HK1061648A1 (en) |
| WO (1) | WO1994028922A1 (en) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9120306D0 (en) | 1991-09-24 | 1991-11-06 | Graham Herbert K | Method and compositions for the treatment of cerebral palsy |
| CA2138020C (en) * | 1992-06-23 | 1999-02-16 | Eric A. Johnson | Pharmaceutical composition containing botulinum b complex |
| DE69429619T2 (en) * | 1993-06-10 | 2002-09-12 | Allergan, Inc. | TREATMENT OF NEUROMUSCULAR DISORDERS AND CONDITIONS WITH BOTULISM SEROTYPE E |
| AU688452B2 (en) * | 1993-12-28 | 1998-03-12 | Allergan, Inc. | Botulinum toxins for treating various disorders and associated pain |
| US6974578B1 (en) | 1993-12-28 | 2005-12-13 | Allergan, Inc. | Method for treating secretions and glands using botulinum toxin |
| US8187612B2 (en) | 1993-12-28 | 2012-05-29 | Allergan, Inc. | Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle |
| US20040126396A1 (en) * | 1993-12-28 | 2004-07-01 | Allergan, Inc. | Botulinum toxin treatment for strabismus |
| US8557256B2 (en) | 1993-12-28 | 2013-10-15 | Allergan, Inc. | Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin |
| US5766605A (en) * | 1994-04-15 | 1998-06-16 | Mount Sinai School Of Medicine Of The City University Of New York | Treatment of autonomic nerve dysfunction with botulinum toxin |
| DE69627963T2 (en) * | 1995-06-06 | 2004-03-04 | Pearce, L. Bruce, Cambridge | IMPROVED COMPOSITIONS AND METHOD FOR CHEMODERVATION WITH NEUROTOXINES |
| EP1053014A4 (en) | 1998-01-26 | 2004-11-10 | Univ Massachusetts | BIOLOGICALLY ACTIVE HEMAGGLUTININ FROM TYPE A $i(CLOSTRIDIUM BOTULINUM) AND METHODS OF USE |
| TW574036B (en) | 1998-09-11 | 2004-02-01 | Elan Pharm Inc | Stable liquid compositions of botulinum toxin |
| US6524580B1 (en) * | 2000-02-15 | 2003-02-25 | Allergan Sales, Inc. | Method for treating thyroid disorders |
| US6358513B1 (en) * | 2000-02-15 | 2002-03-19 | Allergan Sales, Inc. | Method for treating Hashimoto's thyroiditis |
| US6306423B1 (en) * | 2000-06-02 | 2001-10-23 | Allergan Sales, Inc. | Neurotoxin implant |
| AU2003272800A1 (en) * | 2002-10-01 | 2004-04-23 | University Of Maryland | Methods for identifying inhibitors of botulinum neurotoxins |
| WO2004078199A1 (en) * | 2003-03-06 | 2004-09-16 | Botulinum Toxin Research Associates, Inc. | Treatment of chronic chalazion and hordeolum with botulinum toxin |
| US20040226556A1 (en) | 2003-05-13 | 2004-11-18 | Deem Mark E. | Apparatus for treating asthma using neurotoxin |
| US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
| US7514088B2 (en) * | 2005-03-15 | 2009-04-07 | Allergan, Inc. | Multivalent Clostridial toxin derivatives and methods of their use |
| US7811584B2 (en) * | 2004-06-30 | 2010-10-12 | Allergan, Inc. | Multivalent clostridial toxins |
| US20080274480A1 (en) * | 2004-08-04 | 2008-11-06 | Allergan, Inc. | Botulinum Toxin Type a Immunoresistant Assay |
| EP1784420B1 (en) | 2004-09-01 | 2008-12-03 | Allergan, Inc. | Degradable clostridial toxins |
| AU2006227816B2 (en) * | 2005-03-15 | 2012-04-05 | Allergan, Inc. | Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems |
| CA2605160A1 (en) | 2005-04-05 | 2006-10-05 | Allergan, Inc. | Clostridial toxin activity assays |
| EP1906923B1 (en) | 2005-07-22 | 2018-01-24 | The Foundry, LLC | Systems and methods for delivery of a therapeutic agent |
| US10052465B2 (en) | 2005-07-22 | 2018-08-21 | The Foundry, Llc | Methods and systems for toxin delivery to the nasal cavity |
| US9511210B2 (en) * | 2006-05-19 | 2016-12-06 | The Foundry, Llc | Apparatus for toxin delivery to the nasal cavity |
| WO2009139739A1 (en) * | 2006-02-14 | 2009-11-19 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions comprising a combination of botulinum toxin a and botulinum toxin b for treating conditions characterized by unwanted or excessive presynaptic neuronal activity or secretion |
| WO2007106115A1 (en) | 2006-03-14 | 2007-09-20 | Allergan, Inc. | Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells |
| US10792344B2 (en) | 2006-06-29 | 2020-10-06 | Merz Pharma Gmbh & Co. Kgaa | High frequency application of botulinum toxin therapy |
| AR061669A1 (en) * | 2006-06-29 | 2008-09-10 | Merz Pharma Gmbh & Co Kgaa | HIGH FREQUENCY THERAPY APPLICATION WITH BOTULIN TOXIN |
| US8483831B1 (en) | 2008-02-15 | 2013-07-09 | Holaira, Inc. | System and method for bronchial dilation |
| WO2009123174A1 (en) * | 2008-03-31 | 2009-10-08 | 財団法人化学及血清療法研究所 | Preparation of type a2 botulinum neurotoxin |
| KR101719824B1 (en) | 2008-05-09 | 2017-04-04 | 호라이라 인코포레이티드 | Systems, assemblies, and methods for treating a bronchial tree |
| US20100124559A1 (en) * | 2008-11-20 | 2010-05-20 | Allergan, Inc. | Early Treatment and Prevention of Increased Muscle Tonicity |
| EP2926757B1 (en) | 2009-10-27 | 2023-01-25 | Nuvaira, Inc. | Delivery devices with coolable energy emitting assemblies |
| AU2010319477A1 (en) | 2009-11-11 | 2012-05-24 | Holaira, Inc. | Systems, apparatuses, and methods for treating tissue and controlling stenosis |
| US8911439B2 (en) | 2009-11-11 | 2014-12-16 | Holaira, Inc. | Non-invasive and minimally invasive denervation methods and systems for performing the same |
| EP2649984A1 (en) | 2012-04-13 | 2013-10-16 | Lipotec, S.A. | Compounds which inhibit neuronal exocytosis |
| BR112014025396B1 (en) | 2012-04-13 | 2020-03-17 | Lubrizol Advanced Materials, Inc. | COMPOUND, COSMETIC OR PHARMACEUTICAL COMPOSITION, AND USE OF A COMPOUND |
| EP2649983A1 (en) | 2012-04-13 | 2013-10-16 | Lipotec, S.A. | Compounds which inhibit neuronal exocytosis (II) |
| EP2649985A1 (en) | 2012-04-13 | 2013-10-16 | Lipotec, S.A. | Compounds which inhibit neuronal exocytosis (III) |
| US9005628B2 (en) | 2012-10-04 | 2015-04-14 | Dublin City University | Biotherapy for pain |
| US9398933B2 (en) | 2012-12-27 | 2016-07-26 | Holaira, Inc. | Methods for improving drug efficacy including a combination of drug administration and nerve modulation |
| GB201312317D0 (en) | 2013-07-09 | 2013-08-21 | Syntaxin Ltd | Cationic neurotoxins |
| US9216210B2 (en) | 2013-12-23 | 2015-12-22 | Dublin City University | Multiprotease therapeutics for chronic pain |
| EP3822286A1 (en) | 2015-01-09 | 2021-05-19 | Ipsen Bioinnovation Limited | Cationic neurotoxins |
| GB201517450D0 (en) | 2015-10-02 | 2015-11-18 | Ipsen Biopharm Ltd | Method |
| GB201607901D0 (en) | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
| EP3263710A1 (en) | 2016-07-01 | 2018-01-03 | Ipsen Biopharm Limited | Production of activated clostridial neurotoxins |
| CN109790204A (en) | 2016-09-29 | 2019-05-21 | 益普生生物制药有限公司 | Heterozygosis neurotoxin |
| JP7186228B2 (en) | 2018-02-26 | 2022-12-08 | イプセン バイオファーム リミテッド | Use of ultrasound to guide injection of non-cytotoxic proteases |
| GB201815844D0 (en) * | 2018-09-28 | 2018-11-14 | Ipsen Biopharm Ltd | Therapeutic & comestic uses of botulinum neurotoxin serotype e |
| GB202103372D0 (en) | 2021-03-11 | 2021-04-28 | Ipsen Biopharm Ltd | Modified clostridial neurotoxins |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2373454A (en) * | 1943-07-09 | 1945-04-10 | Squibb & Sons Inc | Method of preparing tetanus toxin |
| US2719102A (en) * | 1949-10-28 | 1955-09-27 | Corn States Serum Company | Clostridium perfringens toxoid and process of making the same |
| US3132995A (en) * | 1961-10-20 | 1964-05-12 | Carter Prod Inc | Endotoxin fractions and method for producing same |
| US4664911A (en) | 1983-06-21 | 1987-05-12 | Board Of Regents, University Of Texas System | Immunotoxin conjugates employing toxin B chain moieties |
| US4713240A (en) * | 1985-04-04 | 1987-12-15 | Research Corporation | Vaccines based on insoluble supports |
| US5055291A (en) * | 1986-11-04 | 1991-10-08 | Baylor College Of Medicine | Compositions for preventing secondary cataracts |
| US4932936A (en) * | 1988-01-29 | 1990-06-12 | Regents Of The University Of Minnesota | Method and device for pharmacological control of spasticity |
| US5053005A (en) | 1989-04-21 | 1991-10-01 | Gary E. Borodic | Chemomodulation of curvature of the juvenile spine |
| US5055302A (en) * | 1990-02-22 | 1991-10-08 | Trustees Of The University Of Pennsylvania | Neuropeptide control of ocular growth |
| US5401243A (en) | 1990-08-21 | 1995-03-28 | Associated Synapse Biologics | Controlled administration of chemodenervating pharmaceuticals |
| US5183462A (en) | 1990-08-21 | 1993-02-02 | Associated Synapse Biologics | Controlled administration of chemodenervating pharmaceuticals |
| GB9120306D0 (en) * | 1991-09-24 | 1991-11-06 | Graham Herbert K | Method and compositions for the treatment of cerebral palsy |
| FR2692475B1 (en) | 1992-06-19 | 2000-04-21 | Montpellier Chirurgie | TOTAL KNEE PROSTHESIS. |
| CA2138020C (en) * | 1992-06-23 | 1999-02-16 | Eric A. Johnson | Pharmaceutical composition containing botulinum b complex |
| DE69429619T2 (en) * | 1993-06-10 | 2002-09-12 | Allergan, Inc. | TREATMENT OF NEUROMUSCULAR DISORDERS AND CONDITIONS WITH BOTULISM SEROTYPE E |
| AU688452B2 (en) | 1993-12-28 | 1998-03-12 | Allergan, Inc. | Botulinum toxins for treating various disorders and associated pain |
-
1994
- 1994-06-07 DE DE69429619T patent/DE69429619T2/en not_active Expired - Lifetime
- 1994-06-07 DE DE69435254T patent/DE69435254D1/en not_active Expired - Lifetime
- 1994-06-07 ES ES03018639T patent/ES2329232T3/en not_active Expired - Lifetime
- 1994-06-07 ES ES04027108T patent/ES2335281T3/en not_active Expired - Lifetime
- 1994-06-07 CA CA002332406A patent/CA2332406C/en not_active Expired - Lifetime
- 1994-06-07 EP EP04027108A patent/EP1508336B1/en not_active Expired - Lifetime
- 1994-06-07 ES ES04027109T patent/ES2335662T3/en not_active Expired - Lifetime
- 1994-06-07 EP EP08002883A patent/EP1941898B1/en not_active Expired - Lifetime
- 1994-06-07 JP JP7502041A patent/JPH08511536A/en active Pending
- 1994-06-07 EP EP04027109A patent/EP1512411B1/en not_active Expired - Lifetime
- 1994-06-07 DE DE69435253T patent/DE69435253D1/en not_active Expired - Lifetime
- 1994-06-07 CA CA002164866A patent/CA2164866C/en not_active Expired - Lifetime
- 1994-06-07 AU AU70878/94A patent/AU689115B2/en not_active Expired
- 1994-06-07 DE DE69435284T patent/DE69435284D1/en not_active Expired - Lifetime
- 1994-06-07 ES ES94920705T patent/ES2168302T3/en not_active Expired - Lifetime
- 1994-06-07 CA CA002310845A patent/CA2310845C/en not_active Expired - Lifetime
- 1994-06-07 ES ES08002883T patent/ES2341140T3/en not_active Expired - Lifetime
- 1994-06-07 DE DE122009000066C patent/DE122009000066I2/en active Active
- 1994-06-07 EP EP01101890A patent/EP1166793A1/en not_active Ceased
- 1994-06-07 EP EP94920705A patent/EP0702561B1/en not_active Expired - Lifetime
- 1994-06-07 DE DE69435235T patent/DE69435235D1/en not_active Expired - Lifetime
- 1994-06-07 EP EP00203295A patent/EP1099445A3/en not_active Ceased
- 1994-06-07 EP EP03018639A patent/EP1374886B1/en not_active Expired - Lifetime
- 1994-06-07 WO PCT/US1994/006397 patent/WO1994028922A1/en active IP Right Grant
-
2001
- 2001-03-15 US US09/812,113 patent/US6872397B2/en not_active Expired - Fee Related
- 2001-04-30 US US09/845,512 patent/US20020010138A1/en not_active Abandoned
-
2004
- 2004-01-05 US US11/064,223 patent/US20050129716A1/en not_active Abandoned
- 2004-06-29 HK HK04104658.1A patent/HK1061648A1/en not_active IP Right Cessation
-
2005
- 2005-05-24 JP JP2005151005A patent/JP2005281317A/en not_active Withdrawn
-
2010
- 2010-01-25 JP JP2010013371A patent/JP2010111703A/en not_active Withdrawn
-
2011
- 2011-08-04 JP JP2011170586A patent/JP2011256193A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1994028922B1 (en) | Treatment of neuromuscular disorders and conditions with different botulinum serotype | |
| DE69633228T2 (en) | BOTULINUM TOXIN DERIVATIVES CAN CHANGE THE PERIFERIAL SENSORY ATHERENT FUNCTIONS | |
| CA2164866A1 (en) | Treatment of neuromuscular disorders and conditions with different botulinum serotype | |
| CA2164626A1 (en) | Multiple botulinum toxins for treating neuromuscular disorders and conditions | |
| Hollister et al. | Withdrawal reactions from chlordiazepoxide (“Librium”) | |
| WO1995017904B1 (en) | Botulinum toxins for treating various disorders and associated pain | |
| CA2114014A1 (en) | Advanced Drug Delivery System and Method of Treating Psychiatric, Neurological and Other Disorders with Carbamazepine | |
| CA2190011A1 (en) | Method for Reduction of Headache Pain | |
| DE69034043D1 (en) | PCP RECEPTOR LIGANDS AND THEIR USE | |
| CA2155933A1 (en) | Pulmonary Administration of sCR1 and Other Complement Inhibitory Proteins | |
| BR9710689A (en) | Process for treating acute diarrhea and for providing therapy to a mammal having diarrhea and therapeutic preparation for reducing diarrhea symptoms | |
| AU2282395A (en) | Nitric oxide donor composition and method for treatment of anal disorders | |
| ATE95424T1 (en) | GLUCOPROTEIN HORMONES MODIFIED BY SITE-DIRECTED MUTAGENESIS AND METHODS OF USE THEREOF. | |
| WO1995019570B1 (en) | Antagonists to insulin receptor tyrosine kinase inhibitor | |
| DE3775298D1 (en) | MICROALLOY STEEL. | |
| DE60140136D1 (en) | Kheiten | |
| DE69620888T2 (en) | Neurotoxins for the treatment of skin diseases in mammals | |
| DE2605576B2 (en) | Process for isolating the proteases papain, chimopapain, lysozyme and proteinase X from the milk juice of Carica papaya and use of the isolated proteases for the production of sterilized and lyophilized orthopedic, neurosurgical or ophthalmological preparations | |
| ATE286405T1 (en) | METHOD FOR PREVENTING THE ADVERSE EFFECTS AND INSENSITIVITY TO THERAPEUTIC USES OF TOXINS | |
| WO1994024279A3 (en) | Agents for the prevention and treatment of huntington's disease and other neurological disorders | |
| UA12425A (en) | Method to treat subarachnoidal hemorrhages | |
| Stonnington | Interdependence | |
| IL127487A0 (en) | Method for treating and preventing neurodegenerative disorders by administering thiazolidinone | |
| Kleven et al. | Unit Pricing Analysis of Behavior Maintained by Cocaine Under a Progressive-Ratio Schedule in Rhesus Monkeys | |
| Lennartz et al. | Distribution pattern of polysaccharide chains and oligosaccharides in pig corneal keratan sulphate proteoglycans |